Serbia extended its tender for the Galenika AD drug company for a fourth time, giving a unit of Canada’s Valeant Pharmaceuticals International Inc. (VRX) until June 14 to file a bid, the Finance Ministry said on its website.
The government first called for bidders on Jan. 15, seeking a partner among drugmakers with operating revenue of at least 200 million euros ($$259.5 million) in 2011.
Galenika cut its 2012 loss to 5.6 billion dinars ($65.2 million) from 13.5 billion dinars a year earlier.
To contact the reporter on this story: Gordana Filipovic in Belgrade at firstname.lastname@example.org
To contact the editor responsible for this story: James M. Gomez at email@example.com